Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. EyePoint Pharmaceuticals Inc shares valued at $29,950 were purchased by Zaderej Karen L. on May 19 ’25. At $5.99 per share, Zaderej Karen L. acquired 5,000 shares. The insider’s holdings grew to 36,500 shares worth approximately $0.33 million following the completion of this transaction.
Also, Zaderej Karen L. purchased 5,000 shares, netting a total of over 29,050 in proceeds. Following the buying of shares at $5.81 each, the insider now holds 31,500 shares.
Before that, Zaderej Karen L. had added 5,000 shares to its account. In a trade valued at $27,350, the Director bought EyePoint Pharmaceuticals Inc shares for $5.47 each. Upon closing the transaction, the insider’s holdings increased to 5,000 shares, worth approximately $0.24 million.
As published in their initiating research note from RBC Capital Mkts on June 17, 2025, EyePoint Pharmaceuticals Inc [EYPT] has been an Outperform and the price target has been revised to $28. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of October 16, 2024, Scotiabank has initiated its “Sector outperform” rating for EYPT. Earlier on August 28, 2024, Jefferies initiated its rating. Their recommendation was “a Buy” for EYPT stock.
Analyzing EYPT Stock Performance
On last trading session,, EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] rose 1.25% to $8.92. The stock’s lowest price that day was $8.62, but it reached a high of $9.14 in the same session. During the last five days, there has been a surge of approximately 1.25%. Over the course of the year, EyePoint Pharmaceuticals Inc shares have jumped approximately 19.73%. Shares of the company reached a 52-week high of $9.60 on 06/17/25 and a 52-week low of $3.91 on 04/09/25.
Support And Resistance Levels for EyePoint Pharmaceuticals Inc (EYPT)
According to the 24-hour chart, there is a support level at 8.62, which, if violated, would cause prices to drop to 8.32. In the upper region, resistance lies at 9.20. The next price resistance is at 9.48. RSI (Relative Strength Index) is 69.13 on the 14-day chart, showing neutral technical sentiment.
Is EyePoint Pharmaceuticals Inc subject to short interest?
Stocks of EyePoint Pharmaceuticals Inc saw a sharp steep in short interest on 2025-05-30 dropping by -2.9 million shares to 7.17 million. Data from Yahoo Finance shows that the short interest on 2025-04-30 was 10.07 million shares. A decline of -40.5% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.51 of the overall float, the days-to-cover ratio (short ratio) decline to 8.51.
Which companies own the most shares of EyePoint Pharmaceuticals Inc (EYPT)?
In terms of EyePoint Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 26 in the next 12 months, up nearly 195.12% from the previous closing price of $8.81. Analysts anticipate EyePoint Pharmaceuticals Inc stock to reach 30 by 2025, with the lowest price target being 22. In spite of this, 4 analysts ranked EyePoint Pharmaceuticals Inc stock as Buy at the end of 2025. On January 22, 2024, JP Morgan assigned a price target of “an Overweight” to the stock and initiated coverage with a $35.
